37 related articles for article (PubMed ID: 2846155)
21. DNA topoisomerase II as a target of antineoplastic drug therapy.
Zwelling LA
Cancer Metastasis Rev; 1985; 4(4):263-76. PubMed ID: 3000574
[TBL] [Abstract][Full Text] [Related]
22. Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes.
Osheroff N; Corbett AH; Elsea SH; Westergaard M
Cancer Chemother Pharmacol; 1994; 34 Suppl():S19-25. PubMed ID: 8070023
[TBL] [Abstract][Full Text] [Related]
23. Does bulk damage to DNA explain the cytostatic and cytotoxic effects of topoisomerase II inhibitors?
Gewirtz DA
Biochem Pharmacol; 1991 Nov; 42(12):2253-8. PubMed ID: 1662508
[No Abstract] [Full Text] [Related]
24. Arachidonic acid as a mediator of some of the actions of phorbolmyristate acetate, a tumor promoter and inducer of differentiation.
Das UN
Prostaglandins Leukot Essent Fatty Acids; 1991 Apr; 42(4):241-4. PubMed ID: 1871174
[TBL] [Abstract][Full Text] [Related]
25. Consequences of the resistance to drug-induced topoisomerase II-mediated DNA cleavage.
Zwelling LA
Toxicol Lett; 1993 Apr; 67(1-3):231-6. PubMed ID: 8383886
[TBL] [Abstract][Full Text] [Related]
26. SUMO: A Swiss Army Knife for Eukaryotic Topoisomerases.
Sun Y; Nitiss JL; Pommier Y
Front Mol Biosci; 2022; 9():871161. PubMed ID: 35463961
[TBL] [Abstract][Full Text] [Related]
27. Etoposide, an anticancer drug involved in therapy-related secondary leukemia: Enzymes at play.
Zhang W; Gou P; Dupret JM; Chomienne C; Rodrigues-Lima F
Transl Oncol; 2021 Oct; 14(10):101169. PubMed ID: 34243013
[TBL] [Abstract][Full Text] [Related]
28. The role of topoisomerase II alpha and beta in drug resistance.
Hochhauser D; Harris AL
Cancer Treat Rev; 1993 Apr; 19(2):181-94. PubMed ID: 8386983
[No Abstract] [Full Text] [Related]
29. Gene activation studied by immunological methods.
Huitfeldt HS; Heyden A; Skarpen E; Thrane EV; Schwarze PE
Environ Health Perspect; 1994 Oct; 102 Suppl 6(Suppl 6):205-7. PubMed ID: 7889849
[TBL] [Abstract][Full Text] [Related]
30. Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
Zwelling LA; Chan D; Hinds M; Mayes J; Silberman LE; Blick M
Cancer Res; 1988 Dec; 48(23):6625-33. PubMed ID: 2846155
[TBL] [Abstract][Full Text] [Related]
31. Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells.
Solary E; Bertrand R; Pommier Y
Leuk Lymphoma; 1994 Sep; 15(1-2):21-32. PubMed ID: 7858500
[TBL] [Abstract][Full Text] [Related]
32. [Antitumor agents targeting mammalian topoisomerases].
Nakano H
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1550-5. PubMed ID: 1651681
[TBL] [Abstract][Full Text] [Related]
33. DNA topoisomerase II as the primary target of anti-tumor anthracyclines.
Zunino F; Capranico G
Anticancer Drug Des; 1990 Nov; 5(4):307-17. PubMed ID: 1963303
[TBL] [Abstract][Full Text] [Related]
34. Intercalator-induced, topoisomerase II-mediated DNA cleavage and its modification by antineoplastic antimetabolites.
Zwelling LA; Silberman L; Estey E
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1041-7. PubMed ID: 2427489
[TBL] [Abstract][Full Text] [Related]
35. [Mechanisms of resistance to DNA topoisomerase II inhibitors].
Kohno K; Takano H; Kuwano M
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1568-73. PubMed ID: 1651684
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
